| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | B47; Epidermal growth factor receptor GRB 7; GRB7 adapter protein; GRB7;;GRB7 |
| WB Predicted band size | 60 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human GRB7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于GRB7抗体的3篇参考文献摘要示例(文献信息为虚构示例，仅供参考)：
---
1. **文献名称**：*GRB7 as a Prognostic Biomarker in HER2-Positive Breast Cancer*
**作者**：Smith A, et al.
**摘要**：本研究利用GRB7特异性抗体通过免疫组化分析乳腺癌组织，发现GRB7与HER2共扩增且高表达，提示其可作为HER2阳性乳腺癌患者预后不良的标志物，并可能参与HER2信号通路的调控。
2. **文献名称**：*Role of GRB7 in EGFR Signaling and Tumor Invasion*
**作者**：Lee B, et al.
**摘要**：通过Western blot和免疫荧光技术结合GRB7抗体，研究证实GRB7与表皮生长因子受体(EGFR)形成复合物，促进下游MAPK通路激活，增强胃癌细胞的迁移和侵袭能力。
3. **文献名称**：*Development of a Monoclonal GRB7 Antibody for Targeted Therapy*
**作者**：Zhang C, et al.
**摘要**：报道了一种新型GRB7单克隆抗体的开发，通过体内实验证明其能特异性抑制GRB7与ErbB2受体的相互作用，显著延缓移植瘤模型中的肿瘤生长，提示其治疗潜力。
---
**注意**：以上文献信息为示例，实际研究中请通过PubMed、Web of Science等数据库检索真实文献(例如搜索关键词“GRB7 antibody”或“GRB7 biomarker”)。真实文献可能涉及GRB7抗体在癌症诊断、信号通路研究或治疗开发中的应用。
The GRB7 (Growth Factor Receptor-Bound Protein 7) antibody is a tool used to detect and study the GRB7 protein, a member of the adaptor protein family involved in intracellular signaling. GRB7 plays a critical role in mediating signal transduction pathways by interacting with receptor tyrosine kinases (RTKs), such as EGFR and HER2. through its SH2 domain. It regulates cellular processes like proliferation, migration, and survival, often by linking activated receptors to downstream effectors like the Ras/MAPK pathway. Overexpression of GRB7 has been implicated in several cancers, including breast, gastric, and esophageal cancers, where it correlates with aggressive tumor behavior and poor prognosis. In HER2-positive breast cancer, GRB7 is co-amplified with HER2 and may contribute to tamoxifen resistance, making it a potential therapeutic target.
GRB7 antibodies are widely utilized in research to investigate its expression patterns, molecular interactions, and pathological roles. They enable techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence to quantify GRB7 levels in tissues or cell lines. Such studies help elucidate its involvement in cancer progression and metastasis. Additionally, GRB7 antibodies support the development of targeted therapies, including peptide inhibitors or antibody-drug conjugates designed to disrupt GRB7-mediated signaling. Recent studies also explore GRB7’s role in non-cancer contexts, such as cardiovascular and metabolic diseases. However, challenges remain in standardizing antibody specificity across experimental models, necessitating careful validation to ensure accurate detection and reproducibility in diverse biological systems.
×
